Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponesimod - Johnson & Johnson Innovative Medicine

Next Previous
X
Search
Drug Profile

Ponesimod - Johnson & Johnson Innovative Medicine

Alternative Names: ACT-128800; Compound 8bo - Actelion; PONVORY; R-3477; RG 3477

Latest Information Update: 05 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
  • Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Graft-versus-host disease
  • Discontinued Plaque psoriasis

Most Recent Events

  • 31 Jul 2024 Vanda Pharmaceuticals announces intention to submit Investigational New Drug (IND) application with the US FDA for Psoriasis
  • 31 Jul 2024 Vanda Pharmaceuticals announces intention to submit Investigational New Drug (IND) application with the US FDA for Ulcerative colitis
  • 08 May 2024 Vanda Pharmaceuticals plans a phase III trial for Psoriasis in the US by the end of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top